CJC-1295 (without DAC) vs TB-500 (Ac-LKKTETQ)
Well Studied vs Moderate Research
synergistic Mechanism-based · 47% CJC-1295 (without DAC) and TB-500 (Ac-LKKTETQ) work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
CJC-1295 (without DAC) TB-500 (Ac-LKKTETQ)
Weight 3,367.97 Da 844 Da
Half-life 30 minutes - 2 hours Not precisely established; effects persist longer than 24 hours
Chain 30 amino acids 7 amino acids
Type GHRH analog Acetylated heptapeptide
Key Benefits
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
TB-500 (Ac-LKKTETQ)
01 Promotes wound healing
02 Enhances cell migration
03 Supports angiogenesis (new blood vessel formation)
04 Reduces inflammation
05 Promotes keratinocyte migration
06 Supports collagen deposition
07 Enhances tissue repair
08 Active region of thymosin beta-4
Dosing Protocols
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
TB-500 (Ac-LKKTETQ)
2-2.5mg per injection / 2x weekly (e.g., Monday and Thursday)
Loading phase 2-2.5 mg 2x weekly for 4-6 weeks
Maintenance 2 mg Weekly or bi-weekly
Side Effects
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
TB-500 (Ac-LKKTETQ)
Injection site reactions
Mild fatigue
Head rush (reported)
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Not authorized for medicinal use
Active cancer (theoretical concern)
Pregnancy or breastfeeding
Prohibited by WADA in sports
Research Evidence
CJC-1295 (without DAC) TB-500 (Ac-LKKTETQ)
Status Well Studied Moderate Research
References 5 studies 4 studies
Latest November 2024 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.